OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

Key Products and Services

• LentiVector™ platform for lentiviral vectors
• inAAVate™ platform for AAV vector development
• Adenovirus and other viral vector services
• Process development, quality assurance, and regulatory support
• Full GMP manufacturing services for clinical and commercial products

OXB's dedication to innovation and quality ensures its leadership in the viral vector space, supporting the advancement of gene therapies that promise transformative patient outcomes.